BCTX

BriaCell Therapeutics Corp. NASDAQ Listed Mar 14, 2012

Healthcare ·Biotechnology ·CA · briacell.com

$3.44

+0.00% vs $3.44

Mkt Cap $29.9M

52w Low $2.60 7.0% of range 52w High $14.68

50d MA $3.35 200d MA $5.37

P/E (TTM) —

EV/EBITDA —

P/B 0.3x

Debt/Equity 0.0x

ROE 721.2%

P/FCF -0.2x

RSI (14) 46.10

ATR (14) $0.23

Beta 1.63

50d MA $3.35

200d MA $5.37

Avg Volume 136.0K

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

SIC Code

2834

CIK (SEC)

1610820

Phone

604 921 1810

Bellevue Centre · West Vancouver, BC V7T 2X1 · CA

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 10, 2026	AMC	-4.84	-2.58	+46.7%	3.81	+0.3%	+13.9%	-0.9%	-1.9%	+3.1%	+4.6%	—
Dec 11, 2025	AMC	—	-4.35	—	10.31	-0.1%	-7.5%	-5.9%	-3.1%	+0.3%	+3.2%	—
Oct 27, 2025	AMC	-12.11	-10.49	+13.4%	13.42	+0.1%	-0.6%	-6.7%	-8.7%	-3.2%	-9.1%	—
Jun 16, 2025	AMC	-17.60	-16.40	+6.8%	31.60	-1.6%	-1.3%	+0.0%	-1.9%	-5.9%	+3.1%	—
Mar 12, 2025	AMC	-19.40	-23.30	-20.1%	36.50	-2.7%	-5.5%	+11.3%	+6.0%	-4.7%	+10.1%	—
Dec 16, 2024	AMC	-0.30	-32.98	-9999.0%	91.22	-4.5%	+6.2%	-4.6%	-5.0%	-4.1%	-5.7%	—
Jul 31, 2024	AMC	—	-0.73	—	112.88	-1.7%	-3.6%	-3.5%	-9.6%	-3.6%	-1.7%	—
Jun 14, 2024	AMC	-82.46	16.49	+120.0%	213.00	+0.0%	+4.2%	-9.5%	-4.5%	-6.6%	-6.3%	—
Mar 18, 2024	AMC	-29.99	-106.45	-255.0%	435.00	-3.1%	-6.6%	-17.3%	+1.8%	+10.5%	+13.1%	—
Dec 14, 2023	AMC	-26.99	-74.96	-177.7%	630.00	+2.9%	-1.7%	+0.0%	-4.6%	+3.6%	-1.7%	—
Jul 31, 2023	AMC	—	-1.70	—	1003.50	-2.8%	+1.6%	+1.6%	-1.2%	-2.5%	-0.9%	—
Jun 14, 2023	AMC	-53.97	-47.98	+11.1%	889.50	-2.0%	+2.2%	-0.5%	-4.6%	-0.6%	+4.1%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Aug 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.21	$8.30	+1.1%	-7.4%	-3.9%	+6.4%	+9.0%	-2.6%
Apr 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$41.90	$41.50	-1.0%	+27.7%	+1.5%	+11.0%	-13.8%	-3.8%
Feb 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$50.20	$72.40	+44.2%	+0.4%	-18.7%	+9.3%	-9.6%	-7.9%
Dec 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$165.00	$102.27	-38.0%	-39.9%	-0.2%	-7.9%	+6.2%	-4.6%
Dec 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$166.50	$159.00	-4.5%	+4.5%	-10.3%	-2.9%	-5.2%	+24.3%
Oct 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$151.50	$144.17	-4.8%	-5.0%	+2.5%	+8.7%	+0.9%	-14.4%
Sep 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$78.50	$81.00	+3.2%	+15.1%	+7.7%	+5.1%	-7.3%	+20.2%
Sep 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$92.93	$289.50	+211.5%	+3.3%	-1.6%	-11.0%	-11.9%	-4.8%
Jun 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$229.50	$232.50	+1.3%	-8.5%	+4.3%	-1.4%	-3.5%	+0.0%
May 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$214.50	$220.50	+2.8%	+0.7%	-4.9%	+12.4%	+3.2%	+6.3%

Institutional (13F) — Top 6 All ↗

#	Manager	Shares	Value	Chg	Period
1	Iridian Asset Management Llc/ct	65,000	$272K	New	Mar 2026
2	Luminarx Capital Management Lp	15,000	$63K	New	Mar 2026
3	Morgan Stanley	7,002	$50K	Added	Dec 2025
4	Ubs Group Ag	11,541	$48K	Added	Mar 2026
5	Wells Fargo & Company/mn	1	$4	New	Mar 2026
6	Royal Bank Of Canada	100	—	—	Mar 2026

Mutual Funds / ETFs (N-PORT) — Top 0 All ↗

No N-PORT holders found.

Data updated apr 24, 2026 8:59pm · Source: financialmodelingprep.com